[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100340314":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":108,"collaborators":11,"id":112,"slug":113,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":114,"sex":119,"minAge":120,"maxAge":11,"enrollmentInfo":121,"targetDuration":11,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":11,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Hospital District of Helsinki and Uusimaa","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL",null,[13,14],"Diagnostic Test: ECG monitoring for 3 weeks","Other: Self-monitoring of BP and self-titration of antihypertensive medication",{"label":16,"type":17,"description":18,"interventionNames":11},"Control","NO_INTERVENTION","Standard diagnostic work-up, follow-up, and treatment of hypertension.",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DIAGNOSTIC_TEST","ECG monitoring for 3 weeks","A 3-week continuous ECG monitoring to detect occult AF.",[9],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Self-monitoring of BP and self-titration of antihypertensive medication","One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.",[9],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Tuomas Lumikari, MD","CONTACT","+35894711","tuomas.lumikari@helsinki.fi",{"name":36,"role":32,"phone":11,"phoneExt":11,"email":37},"Anu Eräkanto","anu.erakanto@hus.fi",[39,58,78,93],{"facility":40,"status":41,"city":42,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Kanta-Häme Central Hospital","RECRUITING","Hämeenlinna","Finland","FI",{"type":46,"coordinates":47},"Point",[48,49],24.46434,60.99596,{"lat":49,"lon":48},[52,55],{"name":53,"role":32,"phone":11,"phoneExt":11,"email":54},"Tiina Alapirtti, MD, PhD","tiina.alapirtti@khshp.fi",{"name":56,"role":32,"phone":11,"phoneExt":11,"email":57},"Elina Laakso, MD","elina.laakso@khshp.fi",{"facility":59,"status":41,"city":60,"state":11,"zip":61,"country":43,"countryCode":44,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Helsinki University Hospital","Helsinki","00290",{"type":46,"coordinates":63},[64,65],24.93545,60.16952,{"lat":65,"lon":64},[68,71,74,76],{"name":69,"role":32,"phone":33,"phoneExt":11,"email":70},"Terhi Saarikoski, RN","terhi.saarikoski@hus.fi",{"name":72,"role":73,"phone":11,"phoneExt":11,"email":11},"Tuomo Nieminen, Prof.","PRINCIPAL_INVESTIGATOR",{"name":75,"role":73,"phone":11,"phoneExt":11,"email":11},"Jukka Putaala, A\u002FProf.",{"name":31,"role":77,"phone":11,"phoneExt":11,"email":11},"SUB_INVESTIGATOR",{"facility":79,"status":41,"city":80,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Hyvinkää Hospital","Hyvinkää",{"type":46,"coordinates":82},[83,84],24.86667,60.63333,{"lat":84,"lon":83},[87,90],{"name":88,"role":32,"phone":11,"phoneExt":11,"email":89},"Terttu Heinkinheimo-Connell, MD, PhD","terttu.heikinheimo-connell@hus.fi",{"name":91,"role":32,"phone":11,"phoneExt":11,"email":92},"Katariina Hirvonen, MD","katariina.hirvonen@hus.fi",{"facility":94,"status":41,"city":95,"state":11,"zip":11,"country":43,"countryCode":44,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Päijät-Häme Central Hospital","Lahti",{"type":46,"coordinates":97},[98,99],25.66151,60.98267,{"lat":99,"lon":98},[102,105],{"name":103,"role":32,"phone":11,"phoneExt":11,"email":104},"Tuomo Nieminen, MD, PhD, Prof.","tuomo.nieminen@gmail.com",{"name":106,"role":32,"phone":11,"phoneExt":11,"email":107},"Anne Kerola, MD, PhD","anne.m.kerola@phhyky.fi",{"type":109,"investigatorFullName":110,"investigatorTitle":111,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Jukka Putaala","Head of Stroke Unit","100340314","empowerment-and-mobile-technology-in-the-control-of-cardiovascular-risk-factors-in-patients-with-ischemic-stroke-100340314",false,"NCT03710902","Empowerment and Mobile Technology in the Control of Cardiovascular Risk Factors in Patients With Ischemic Stroke","CARDIOSTROKE","Inclusion Criteria:\n\n* Ischemic stroke or transient ischemic attack (ABCD2 score ≥3)\n* Age ≥40 years\n* Pre-existing or newly diagnosed hypertension\n* Informed consent from the patient or legal representative\n\nExclusion Criteria:\n\n* Known high-risk source of cardioembolism\n* Known indication for anticoagulation\n* Contraindication for anticoagulation\n* Pacemaker\n* Non-compliance to study interventions as judged by the investigator\n* Serious condition hampering the study conduct","ALL","40 Years",{"count":122,"type":123},405,"ESTIMATED","INTERVENTIONAL",[126],"NA","The CARDIOSTROKE is a randomized trial comparing mobile-device assisted control of hypertension together with screening of occult atrial fibrillation to standard care in patients with recent ischemic stroke or transient ischemic attack.",[129,130,131,132,133],"Ischemic Stroke","Transient Ischemic Attack","Atrial Fibrillation","Hypertension","Empowerment","2025-03-18",{"date":136,"type":137},"2025-03-20","ACTUAL",{"date":139,"type":137},"2018-10-17",{"date":141,"type":123},"2028-09",{"name":110,"class":6},4]